Tag: Cleveland Clinic

Poster-Symptom Management

Sources of Cannabis Information and Medical Guidance Among People with Multiple Sclerosis: Narcoms Survey Results

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people...

Read More

Poster-Relapse Therapy

Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to...

Read More

Poster-Quality of Life and Outcomes

Gratitude, Perceived Stress, and Quality of Life Among Patients with MS

Background: Multiple sclerosis (MS) is characterized by an unpredictable course of neurological symptoms that are thought to be exacerbated...

Read More

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More

Poster-Disease-modifying Therapy

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Platform-Disease Management

Prevalence of Cannabis Use and Associated Factors Among People with Multiple Sclerosis: A 2020 NARCOMS Survey

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people...

Read More